ecteinascidin 743 has been researched along with Neoplasms, Pleural in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, J; Ahlenc-Gelas, M; Cavalcanti, A; Domitrescu, G; Dumont, S; El Amarti, L; Honore, C; Kiavue, N; Klausner, G; Le Cesne, A; Mir, O; Sourrouille, I; Terrier, P; Verret, B | 1 |
| Badalamenti, G; Bello, E; Casali, PG; Collini, P; Colombo, C; Cominetti, D; D'Incalci, M; Dagrada, GP; Dei Tos, AP; Frapolli, R; Gronchi, A; Morosi, C; Negri, T; Pilotti, S; Provenzano, S; Renne, SL; Saponara, M; Stacchiotti, S; Tortoreto, M; Vincenzi, B; Zaffaroni, N; Zuco, V | 1 |
2 other study(ies) available for ecteinascidin 743 and Neoplasms, Pleural
| Article | Year |
|---|---|
Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series.
Topics: Adult; Antineoplastic Agents, Alkylating; Desmoplastic Small Round Cell Tumor; Dioxoles; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2017 |
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar Neoplasms; Dacarbazine; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Furans; Humans; Ifosfamide; Ketones; Kidney Neoplasms; Male; Meningeal Neoplasms; Mice, SCID; Middle Aged; Pleural Neoplasms; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |